Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Subudhi, Bharat Bhusan
- Repurposing of Aspirin:Opportunities and Challenges
Abstract Views :168 |
PDF Views:0
Authors
Affiliations
1 Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, IN
1 Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 2037-2044Abstract
Repurposing refers to the study of drugs which is already approved to treat one disease for the treatment of other diseases. Aspirin (ASA) is widely used for the treatment of pain, fever or inflammation. It has been repurposed against cardiovascular disorders. In recent years ASA has generated a significant interest for prevention of cancer, central nervous system disorder, diabetes and cryptococcal infection due to its influence on COX dependent and COX independent mechanism. Following oral administration ASA is rapidly hydrolyzed to salicylic acid (SA). Since SA has selective ability to inhibit COX-2, its application for repurposing is limited. Besides, ASA is more potent due to its capacity for irreversible inhibition of COX. Thus for repurposing it is desirable to ensure adequate availability of ASA at site of action. This is a challenge as issues related to solubility, stability and toxicity needs to be simultaneously addressed while repurposing.Keywords
Aspirin, Salicylic Acid, Arachidonic Acid, Prostaglandin, Thromboxane, Gastrotoxicity, Central Nervous System, Diabetes.
References
- Wood JN. From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’. Phil. Trans. R. Soc. B. 2015; 370 (1666):20140317.
- Tsoucalas G, Karamanou M, Androutsos G. Travelling through time with aspirin, a healing companion. Eur J Inflamm. 2011; 9(1): 13-16
- Hemler MA, Lands WE. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem. 1976; 251(18):5575-5579.
- Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014; 111(1):61.
- Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T. Gene transfer of thromboxane A2 synthase and prostaglandin I2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002; 1; 62(1):63-66.
- Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 1980; 1; 17(3-4):317-327.
- Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10(7):489.
- Ulrych T, Böhm A, Polzin A, Daum G, Nusing RM, Geisslinger G, Hohlfeld T, Schror K, Rauch BH. Release of sphingosine1phosphate from human platelets is dependent on thromboxane formation. J. Thromb. Haemost. 2011; 9(4):790-798.
- Menter DG, Steinert BW, Sloane BF, Gundlach N, O'Gara CY, Marnett LJ, Diglio C, Walz D, Taylor JD, Honn KV. Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Res. 1987 15; 47(24 Part 1):6751-6762.
- Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004; 109(12):1468-1471.
- Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proceedings of the National Academy of Sciences. 1998 20; 95 (2):681-686.
- Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Jama. 2005 24; 294(8):914-923.
- Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J. Natl. Cancer Inst. 1996 17; 88(14):988-993.
- Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995 1; 9(13):1586-1597.
- Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents’ aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998; 396(6706):77.
- Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of β-catenin–T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proceedings of the National Academy of Sciences. 1999 16; 96(4):1603-1608.
- Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, Peppelenbosch MP, Hardwick JC. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006; 25(49):6447.
- Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012; 142(7):1504-1515.
- Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012; 336(6083):918-922.
- Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci. 2009; 30(4):174-181.
- Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004 1; 63(9):901-910.
- Rizwan S, Idrees A, Ashraf M, Ahmed T. Memory-enhancing effect of aspirin is mediated through opioid system modulation in an AlCl3-induced neurotoxicity mouse model. Exp Ther Med. 2016 1; 11(5):1961-1970.
- Nakajima H, Itakura M, Kubo T, Kaneshige A, Harada N, Izawa T, Azuma YT, Kuwamura M, Yamaji R, Takeuchi T. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) aggregation causes mitochondrial dysfunction during oxidative stress-induced cell death. J. Biol. Chem. 2017 6: jbc-M116.
- Choi HW, Tian M, Manohar M, Harraz MM, Park SW, Schroeder FC, Snyder SH, Klessig DF. Human GAPDH is a target of aspirin’s primary metabolite salicylic acid and its derivatives. PLoS One. 2015; 10(11):e0143447.
- Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP‐induced dopamine depletion in mice. J. Neurochem. 1998; 71(4):1635-1642.
- Verma S, Chandra H, Banerjee M. Cyclooxygenase 1 (COX1) expression in Type 2 diabetes mellitus: A preliminary study from north India. Eur J Med Genet. 2016; 17(1):41-45.
- Persaud SJ, Burns CJ, Belin VD, Jones PM. Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes. 2004 1; 53(suppl 1):S190-192
- Tabatabaie T, Waldon AM, Jacob JM, Floyd RA, Kotake Y. COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. Biochem. Biophys. Res. Commun. 2000 5; 273(2):699-704.
- Layla Amiri, Annie John, Jasmin Shafarin, Ernest Adeghate, Petrilla Jayaprakash Javed Yasin, Frank Christopher, Howarthc Haider Raza . Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. Cell. Physiol. Biochem. 2015; 36:1939-1950.
- Patel S, Santani D. Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep. 2009 1; 61(4):595-603.
- Ertugrul DT, Tutal E, Yıldız M, Akin O, Yalçın AA, Ure OS, Yılmaz H, Yavuz B, Deveci OS, Ata N, Kuçukazman M. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2010; 95(6):2897-2901.
- Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 2002 15; 109(10):1321-1326.
- Ogundeji AO, Pohl CH, Sebolai OM. The repurposing of aspirin and ibuprofen as candidate anti-cryptococcus drugs. Antimicrobial agents and chemotherapy. 2016: AAC-02810.
- Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 2014; 22(3):120-127.
- Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999 1; 12(4):501-517.
- Kock JL, Sebolai OM, Pohl CH, Van Wyk PW, Lodolo EJ. Oxylipin studies expose aspirin as antifungal. FEMS yeast research. 2007 1; 7(8):1207-1217.
- Kock JL, Strauss CJ, Pohl CH, Nigam S. The distribution of 3-hydroxy oxylipins in fungi. Prostaglandins Other Lipid Mediat. 2003 1; 71(3-4):85-96.
- Codon AC, Gasent-Ramirez JM, Benitez T. Factors which affect the frequency of sporulation and tetrad formation in Saccharomyces cerevisiae baker's yeasts. Appl. Environ. Microbiol. 1995; 61(2):630-638.
- Levy G. Absorption, metabolism and excretion of salicylates. The salicylates. 1966:5-48.
- Mayersohn M. Aspirin. J Am Pharm Assoc 1977; NS17: 107-112.
- Orton D, Jones TR, Kaspi T, Richardson R. Plasma salicylate levels after soluble and effervescent aspirin. Br J Clin Pharmacol. 1979 1; 7(4):410-412.
- Sansom LN. Pharmacokinetics of salicylates. Aust J Pharm 1983; 6: 510-514.
- Schanker LS, Tocco DJ, Brodie BB, Hogben CA. Absorption of drugs from the rat small intestine. J. Pharmacol. Exp. Ther. 1958 1; 123(1):81-88.
- Wood J. Effect of food on aspirin absorption. The Lancet. 1967 22; 290 (7508):212.
- Volans GN. Effects of food and exercise on the absorption of effervescent aspirin. Br J Clin Pharmacol. 1974; 1(2):137-141.
- Garabedian-Ruffalo SM, Syrja-Farber M, Lanius PM, Plucinski A. Monitoring of drug-drug and drug-food interactions. Am J Health Syst Pharm. 1988; 45(7):1530-1547.
- Sharma HL and Sharma K. Principles of Pharmacology. Paras medical Publisher, 2nd edition. Hyderabad. pp.366
- Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016 4; 11(8):e0160046.
- Alexander Galat, 126 Buckingham Rd., Yonkers, N.Y. United States Patent, Patent Number: 5,776,431.
- Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci. 1972; 61(3):379-385.
- Rowland M, Riegelman S. Determination of acetylsalicylic acid and salicylic acid in plasma. J Pharm Sci. 1967; 56(6):717-20.
- Harris PA, Riegelman S. Influence of the route of administration on the area under the plasma concentration time curve. J Pharm Sci. 1969; 58(1):71-75.
- Rainsford KD. "Aspirin and the Salicylates". Butterworths, London; 1984.
- Rainsford KD, Schweitzer A, Brdne K. Distribution of the acetyl compared with the salicyl moiety of acetylsalicylic acid: Acetylation of macromolecules in organs wherein side-effects are manifest. Biochem. Pharmacol. 1983 1; 32(7):1301-1308.
- Levy G, Tsuchiya T, Amsel LP. Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin. Pharmacol. Ther. 1972 1; 13(2):258-268.
- Cook NR, Chae C, Mueller FB, et al. Mis-medication and Under-utilization of Aspirin in the Prevention and Treatment of Cardiovascular Disease.Med. Gen. Med. 1999.
- Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. In Prospects for chemoprevention of colorectal neoplasia 2013 (pp. 39-65). Springer, Berlin, Heidelberg.
- Charman WN, Charman SA, Monkhouse DC, Frisbee SE, Lockhart EA, Weisman S, Fitzgerald GA. Biopharmaceutical characterisation of a low dose (75 mg) controlled release aspirin formulation. Br J Clin Pharmacol. 1993; 36(5):470-473.
- Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystolic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 1984; 311(19):1206-1211.
- Seymour RA, Rawlins MD. Efficacy and pharmacokinetics of aspirin in post operative dental pain. Br J Clin Pharmacol. 1982; 13(6):807-810.
- Smyth MJH, Dawkins PD (1971) Salicylates and enzyme. J Pharm Pharmacol 23:729–744.
- Rumble RH, Brooks PM, Roberts MS. Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol. 1980; 9(1):41-45.
- Chiabrando C, Castelli MG, Cozzi E, Fanelli R, Campoleoni A, Balotta C, Latini R, Garattini S. Anti-inflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. Eur. J. Pharmacol. 1989 17; 159(3):257-264.
- Dubovska D, Piotrovskij VK, Gajdos M, Krivosikova Z, Spustova V, Trnovec T. Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Methods Find Exp Clin Pharmacol. 1995; 17(1):67-77.
- Hinz B, Kraus V, Pahl A, Brune K. Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E2 synthesis in murine macrophages. Biochem. Biophys. Res. Commun. 2000 21; 274(1):197-202.